house dust mite disease epidemiology forecast
Key Highlights
- The major allergenic HDM species include Dermatophagoides pteronyssinus (D. pteronyssinus), Dermatophagoides farinae (D. farinae), and Euroglyphus maynei (E. maynei). Among these, D. pteronyssinus and D. farinae are recognized as the primary allergen sources worldwide, responsible for the majority of sensitization cases in allergic individuals.
- In contrast, Blomia tropicalis (B. tropicalis) thrives only in hot and highly humid climates, making it prevalent in tropical and subtropical regions while remaining rare in temperate zones.
- To date, approximately 40 groups of HDM allergens have been identified and registered by the World Health Organization (WHO)/International Union of Immunological Societies (IUIS) Allergen Nomenclature Sub-Committee.
- HDM allergy is diagnosed through clinical history, Skin Prick Tests (SPTs), and specific IgE testing. The use of recombinant allergens and Component-resolved Diagnostics (CRD) improves accuracy by identifying specific sensitizations, distinguishing cross-reactivity, and supporting Allergen immunotherapy (AIT) monitoring.
- HDM allergy is present in up to 90% of Asian atopic patients, far exceeding that which is seen in Western populations which report prevalence of only 50 to 70%.
- Female predominance in adult allergic diseases is likely influenced by hormonal factors such as estrogen, which modulate immune responses and heighten sensitivity to HDM and other allergens, along with differential environmental exposures and health-seeking behaviour patterns contributing to higher diagnosed prevalence in women.
DelveInsight’s “House Dust Mite Disease (HDMD)– Epidemiology Forecast – 2034” report delivers an in-depth understanding of HDMD, historical and forecasted epidemiology of HDMD in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, Japan, and China.
Geography Covered
- The United States
- EU4 (Germany, France, Italy, and Spain) and the United Kingdom
- Japan
- China
Study Period: 2020–2034
House Dust Mite Disease (HDMD) Disease Understanding
House Dust Mite Disease (HDMD) Overview
Dust mite allergy is an allergic condition that occurs as a reaction to the dust mite allergens that commonly live in household dust. It is also known as house dust allergy. It is a sensitization and an allergic reaction to the droppings of the dust mites. The droppings are an indoor aeroallergen, which, on inhalation, triggers the allergic reaction. The HDM is a predominant source of indoor aeroallergens. Some of the allergic diseases that have been associated with the HDM are allergic rhinoconjunctivitis, allergic asthma, and atopic dermatitis. The best treatment strategy for allergic rhinitis consists of allergen avoidance first, in conjunction with pharmacotherapy and allergen immunotherapy. The untreated HDM allergy may lead to the development of severe disease manifestations such as atopic dermatitis or asthma. Diagnosis and immunotherapy of HDM allergic patients are well established, but are often hampered by the use of mite extracts that are of poor quality and lack important allergens.
House Dust Mite Disease (HDMD) Diagnosis
Diagnosis of HDM allergy is based on a combination of clinical evaluation and allergen-specific testing. A detailed medical history and symptom assessment help establish a link between exposure to dust and allergic manifestations such as rhinitis, asthma, or dermatitis. Diagnostic confirmation typically involves skin prick testing or measurement of serum-specific IgE antibodies against HDM allergens, such as D. pteronyssinus and D. farinae. In certain cases, component-resolved diagnostics may be used to identify sensitization to specific allergenic proteins, improving diagnostic precision. Environmental exposure assessment and, when needed, nasal or bronchial provocation tests can further support diagnosis. Accurate identification of HDM sensitization is essential for guiding targeted treatment strategies, including allergen immunotherapy and environmental control measures.
House Dust Mite Disease (HDMD) Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total prevalent population of HDMD, total diagnosed prevalent population of HDMD, gender-specific diagnosed prevalent population of HDMD, allergen-specific diagnosed prevalent population of HDMD, and total treated cases of HDMD in the 7MM + China market covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Japan, and China from 2020 to 2034.
- In 2024, the diagnosed prevalent population of asthma in the 7MM was approximately 113 million. This number is expected to rise through 2034, driven by advances in complement biology, improved diagnostics, and wider use of genetic testing, complement assays, and multidisciplinary biopsy evaluation.
- The diagnosed prevalent population of allergic rhinitis, in the United States, was found to be 25 million in 2024.
- The diagnosed prevalent population of atopic dermatitis in China were nearly 113 million cases in 2024.
- In 2024, the prevalent population of HDMD was estimated at 40 million cases. This prevalence is influenced by widespread exposure to HDM in indoor environments, increasing rates of atopy, urbanization, and changing lifestyles that favour prolonged indoor activities.
- In EU4 and the UK, among allergen-specific diagnosed HDM cases, Der p 2 was the most prevalent allergen, detected in approximately 92% of allergic individuals, while Der p 23 accounted for a lower share, at nearly 82%.
Scope of the Report
- The report covers a segment of key events, an executive summary, descriptive overview of HDMD, explaining its causes, signs and symptoms, pathogenesis, and diagnostic approaches.
- Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.
- A detailed review of the HDMD epidemiology, detailed assumptions, and rationale behind our approach is included in the report.
- A detailed review of current challenges in establishing the diagnosis.
House Dust Mite Disease (HDMD) Report Insights
- Patient Population
- Patient population by gender and age
- Country-wise Epidemiology Distribution
Report Key Strengths
- 10 Years Forecast
- The 7MM + China Coverage
- HDMD Epidemiology Segmentation
House Dust Mite Disease (HDMD) Report Assessment
- Epidemiology Segmentation
- Current Diagnostic Practices
FAQs
- What are the disease risks and burdens of HDMD epidemiology? What will be the growth opportunities across the 7MM and China with respect to the patient population about HDMD epidemiology?
- What is the historical and forecasted to HDMD epidemiology patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, Japan, and China?
- Which age group is the largest contributor to patients affected with HDMD epidemiology?
Reasons to Buy
- Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
- To understand Key Opinion Leaders’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
- Detailed insights into various factors hampering disease diagnosis and other existing diagnostic challenges.
